# A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy

Study · id `cardio:ct-nct01252056` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01252056](<https://clinicaltrials.gov/study/NCT01252056>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01252056

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

## Technical summary

Registry record NCT01252056. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 353 participants (enrolled count; ClinicalTrials.gov record NCT01252056, source copy `cardio:ctgov-nct01252056-2013-05-08`, retrieved 2026-10-26)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01252056, source copy `cardio:ctgov-nct01252056-2013-05-08`, retrieved 2026-10-26)
- Primary completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01252056, source copy `cardio:ctgov-nct01252056-2013-05-08`, retrieved 2026-10-26)
- Completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01252056, source copy `cardio:ctgov-nct01252056-2013-05-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01252056, source copy `cardio:ctgov-nct01252056-2013-05-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01252056-2013-05-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
- Condition: Diabetic Nephropathy
- Intervention (Drug): Probucol
- Intervention (Drug): Probucol and Cilostazol
- Lead sponsor: Otsuka Beijing Research Institute
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Otsuka Beijing Research Institute (`cardio:org-otsuka-beijing-research-institute`)

## Provenance

Content hash: 9db5237f971255fc8fad4a59654ee35a138ddea0bf364ed3475624386d631797
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
